7XI7
Human dihydrofolate reductase complexed with P39
Summary for 7XI7
| Entry DOI | 10.2210/pdb7xi7/pdb |
| Descriptor | Dihydrofolate reductase, 6-hexyl-5-phenyl-pyrimidine-2,4-diamine, SULFATE ION, ... (4 entities in total) |
| Functional Keywords | human dhfr, dihydrofolate reductase, p39, oxidoreductase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 1 |
| Total formula weight | 22039.28 |
| Authors | Vanichtanankul, J.,Saeyang, T.,Kamchonwongpaisan, S.,Yuvaniyama, J.,Yuthavong, Y. (deposition date: 2022-04-12, release date: 2022-06-29, Last modification date: 2023-11-29) |
| Primary citation | Vanichtanankul, J.,Yoomuang, A.,Taweechai, S.,Saeyang, T.,Pengon, J.,Yuvaniyama, J.,Tarnchompoo, B.,Yuthavong, Y.,Kamchonwongpaisan, S. Structural Insight into Effective Inhibitors' Binding to Toxoplasma gondii Dihydrofolate Reductase Thymidylate Synthase. Acs Chem.Biol., 17:1691-1702, 2022 Cited by PubMed Abstract: Pyrimethamine (Pyr), a known dihydrofolate reductase (DHFR) inhibitor, has long been used to treat toxoplasmosis caused by (Tg) infection. However, Pyr is effective only at high doses with associated toxicity to patients, calling for safer alternative treatments. In this study, we investigated a series of Pyr analogues, previously developed as DHFR inhibitors of bifunctional DHFR-thymidylate synthase (PfDHFR-TS), for their activity against DHFR-TS (TgDHFR-TS). Of these, a set of compounds with a substitution at the position of the pyrimidine ring exhibited high binding affinities (in a low nanomolar range) against TgDHFR-TS and inhibitory activity. Three-dimensional structures of TgDHFR-TS reported here include the ternary complexes with Pyr, P39, or P40. A comparison of these structures showed the minor steric strain between the -chlorophenyl group of Pyr and Thr83 of TgDHFR-TS. Such a conflict was relieved in the complexes with the two analogues, P39 and P40, explaining their highest binding affinities described herein. Moreover, these structures suggested that the hydrophobic environment in the active-site pocket could be used for drug design to increase the potency and selectivity of antifolate inhibitors. These findings would accelerate the development of new antifolate drugs to treat toxoplasmosis. PubMed: 35715223DOI: 10.1021/acschembio.1c00627 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.65 Å) |
Structure validation
Download full validation report
